Novel Immunotherapy-Based Combination Approaches in Advanced NSCLC: Expanding Options for Durable Outcomes

Join us for a live webinar designed to support oncology clinicians in navigating the evolving treatment landscape of advanced non-small cell lung cancer (NSCLC). Nationally renowned NSCLC experts will explore the integration of novel immunotherapy-based combination regimens, including antibody-drug conjugates, targeted therapies, and immune checkpoint inhibitors, into personalized treatment plans. The program will emphasize the role of biomarkers, including PD-L1, in guiding therapeutic decisions and providing evidence-based strategies for managing the distinct toxicities associated with these therapies. Don't miss the opportunity to hear leading strategies for integrating the latest clinical evidence into advanced NSCLC care and have your most pressing questions answered.